Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Bicycle Therapeutics (BCYC) Profit After Tax (2018 - 2025)

Bicycle Therapeutics (BCYC) has disclosed Profit After Tax for 8 consecutive years, with -$59.1 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Profit After Tax fell 16.39% year-over-year to -$59.1 million, compared with a TTM value of -$250.7 million through Sep 2025, down 50.77%, and an annual FY2024 reading of -$169.0 million, up 6.44% over the prior year.
  • Profit After Tax was -$59.1 million for Q3 2025 at Bicycle Therapeutics, up from -$79.0 million in the prior quarter.
  • Across five years, Profit After Tax topped out at -$14.7 million in Q3 2021 and bottomed at -$79.0 million in Q2 2025.
  • Average Profit After Tax over 5 years is -$38.3 million, with a median of -$39.1 million recorded in 2023.
  • The sharpest move saw Profit After Tax skyrocketed 32.0% in 2024, then plummeted 128.72% in 2025.
  • Year by year, Profit After Tax stood at -$18.0 million in 2021, then plummeted by 66.2% to -$30.0 million in 2022, then tumbled by 63.78% to -$49.1 million in 2023, then fell by 5.62% to -$51.9 million in 2024, then fell by 13.97% to -$59.1 million in 2025.
  • Business Quant data shows Profit After Tax for BCYC at -$59.1 million in Q3 2025, -$79.0 million in Q2 2025, and -$60.8 million in Q1 2025.